肾脏选择性 AMPK 激活剂治疗多囊肾病-猫眼课题宝

肾脏选择性 AMPK 激活剂治疗多囊肾病

批准号：

8646478

负责人：

Ken W Batchelor

金额：

$41.51万

依托单位：

NOVATARG, INC.

依托单位国家：

美国

项目类别：

财政年份：

2013

资助国家：

美国

项目状态：

已结题

起止时间：

2013-09-16 至 2014-06-30

来源：

https://reporter.nih.gov/project-details/8646478

关键词：

2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole AVPR2 gene Affinity Animal Model Anions Autosomal Dominant Polycystic Kidney Biguanides Biological Assay Biology Blood Cell Culture Techniques Cell Proliferation Cell membrane Cells Characteristics Chemicals Chronic Clinical Trials Collaborations Collagen Complication Cyst Cystic Fibrosis Transmembrane Conductance Regulator Data Dialysis procedure Diffusion Disease Drug Design Embryo Evaluation Fluids and Secretions Future Growth Human In Vitro Inhibition of Cell Proliferation Innovative Therapy Institutes Kansas Kidney Lactic Acidosis Lead Life Style Ligands Liver Mediating Medical center Metformin Methods Modification Organ Culture Techniques Organic Cation Transporter Outcome POU2F1 gene POU2F2 gene Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Pharmacotherapy Phase Phosphorylation Polycystic Kidney Diseases Polyuria Process Renal Mass Renal function Series Structure-Activity Relationship System Testing Thirst Transplantation Universities Urination Urine V2 Receptors Water analog base cell growth compliance behavior cost design effective therapy experience human FRAP1 protein interest kidney pharmacology novel novel strategies programs public health relevance screening uptake

中文摘要

翻译

描述（由申请人提供）：全球约有1200万人患有常染色体显性多囊肾病（ADPKD）。ADPKD是一种慢性疾病，目前尚无有效的药物治疗方法；在美国，每年进行透析和移植的费用为100亿至20亿美元。NovaTarg开发了一种新的肾脏选择性PKD治疗方法，有望产生阻断潜在疾病过程的药物，并为PKD患者提供创新疗法。

英文摘要

DESCRIPTION (provided by applicant): There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of >$2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文